AMRI has expanded into the protein market, with an initial focus on protein expression and purification. AMRI’s current and ongoing activities, as part of its New York State Public-Private Partnership in Buffalo, New York, encompass the production of purified recombinant proteins as reagents and tools for biological assays and sterile, pyrogen-free materials fproof-of-concept, non-human in vivo studies. Current production capabilities range from a scale of 1 to 100 milligrams. The protein expression systems and methods of focus are E. coli, mammalian and baculovirus.

As part of its aim to provide  high-value services in the area of biology and pharmacology, AMRI introduced an investigational new drug (IND)-enabling support services platform in March 2014. This platform of services is aimed at supporting the successful initiation and completion of customer IND programs. As part of this offering, AMRI now provides in vitro drug metabolism and pharmacokinetics (DMPK) studies related to drug-drug interactions and metabolism, which are routinely included in IND submissions.

Source: AMRI